psychiatryПСИХИАТРИЯPsychiatry (Moscow) (Psikhiatriya)1683-83192618-6667FSBSI “The Mental Health Research Centre”; LLC «Publisher «MIA»10.30629/2618-6667-2016-72-55-69psychiatry-237Research ArticleНАУЧНЫЕ ОБЗОРЫSCIENTIFIC REVIEWSНейроэндокринные аспекты патогенеза и психофармакотерапии панического расстройстваПавловаТатьяна Алексеевнаpava-6@yandex.ruДоровскихИгорь Владимировичig.dorovskih@yandex.ruГоробецЛюдмила Николаевнаgorobetsln@mail.ruФГКУ «1586 военный клинический госпиталь» Минобороны РФRussian FederationФГБУ «ФМИЦПН им. В.П. Сербского» Минздрава РФRussian Federation2016281220160725569Copyright © Павлова Т.А., Доровских И.В., Горобец Л.Н., 20162016Павлова Т.А., Доровских И.В., Горобец Л.Н.Павлова Т.А., Доровских И.В., Горобец Л.Н.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.journalpsychiatry.com/jour/article/view/237

Обоснование: в развитии панического расстройства играет роль накопление гормонов стресса - кортизола и пролактина, а также циклические изменения уровня эстрогена.Цель: представить обзор доказательных исследований нейроэндокринных основ патогенеза панического расстройства, доступ к которым получен через базы данных Pubmed и Medline.Результаты: рассмотрены современные взгляды на терапию панического расстройства, в частности на оценку эффективности различных групп антидепрессантов. Приведены данные литературы о возможных нейроэндокринологических и метаболических нарушениях, сопряженных с применением антидепрессантов различного механизма действия. По результатам анализа публикаций показано, что практически все антидепрессанты влияют на уровень пролактина, тиреоидных гормонов, гормонов ГГА-оси и существенно увеличивают риск развития метаболического синдрома и сахарного диабета 2-го типа.

Background: in development of panic disorder the accumulation of hormones of a stress - cortisol and prolactinum, as well as the cyclic changes of estrogen level plays a role.The aim was to review the results of researches on neuroendocrine bases of pathogenesis of panic disorder, access to which is got through the Pubmed and Medline databases.Results: modern views on therapy of panic disorder, in particular, efficiency of various groups of antidepressants are considered. The possible neuroendocrinological and metabolic disturbances interfaced to use of antidepressants of various mechanism of action are estimated. It is shown that practically all antidepressants influence prolactinum level, thyroid hormones, hormones of the GPA-axis and significantly increase risk of development of a metabolic syndrome and diabetes of the 2 type.

паническое расстройствопатогенезгормоныпсихофармакотерапияантидепрессантынейроэндо- кринные побочные эффектыpanic disorderpathogenesishormonespsychopharmacotherapyantidepressantsneuroendocrine side effectsReferencesAndlin-Sobocki P., Wittchen H.U. Cost of anxiety in Europe. European Journal of Neurology. 2005;12:39-44. DOI:10.1111/j.1468-1331.2005.01196.xAndlin-Sobocki P., Wittchen H.U. Cost of anxiety in Europe. European Journal of Neurology. 2005;12:39-44. DOI:10.1111/j.1468-1331.2005.01196.xKessler R.C., Chiu W.T., Jin R., Ruscio A.M., Shear K., Wal- ters E.E. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Rep- lication. Archives General Psychiatry. 2006;63:415-424. DOI:10.1001/archpsyc.63.4.415Kessler R.C., Chiu W.T., Jin R., Ruscio A.M., Shear K., Wal- ters E.E. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Rep- lication. Archives General Psychiatry. 2006;63:415-424. DOI:10.1001/archpsyc.63.4.415Locke A.B., Kirst N., Shultz C. Diagnosis and management of generalized anxiety disorder and panic disorder in adults. American Family Physician. 2015;91(9):617-624Locke A.B., Kirst N., Shultz C. Diagnosis and management of generalized anxiety disorder and panic disorder in adults. American Family Physician. 2015;91(9):617-624Барлоу Д. Клиническое руководство по психическим расстройствам. СПб.: «Питер»; 2010Барлоу Д. Клиническое руководство по психическим расстройствам. СПб.: «Питер»; 2010Kessler R.C., Petukhova M., Sampson N.A., Zaslavsky A.M., Wittchen H.-U. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. International Journal of Methods in Psychiat- ric Research. 2012;21(3):169-184. DOI:10.1002/mpr.1359Kessler R.C., Petukhova M., Sampson N.A., Zaslavsky A.M., Wittchen H.-U. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. International Journal of Methods in Psychiat- ric Research. 2012;21(3):169-184. DOI:10.1002/mpr.1359American psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th ed.) (DSM-V). APA; 2013American psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th ed.) (DSM-V). APA; 2013Tilli V., Suominen K., Karlsson H. Panic disorder in primary care: Comorbid psychiatric disorders and their persistence. Scandinavian Journal of Primary Health Care. 2012;30:247- 253. DOI:10.3109/02813432.2012.732471Tilli V., Suominen K., Karlsson H. Panic disorder in primary care: Comorbid psychiatric disorders and their persistence. Scandinavian Journal of Primary Health Care. 2012;30:247- 253. DOI:10.3109/02813432.2012.732471Kelly M.M., Forsyth J.P., Karekla M. Sex differences in re- sponse to a panicogenic challenge procedure: an exper- imental evaluation of panic: vulnerability in a non-clin- ical sample. Behaviour Research and Therapy. 2006; 44(10):1421-1430. DOI:10.1016/j.brat.2005.10.012Kelly M.M., Forsyth J.P., Karekla M. Sex differences in re- sponse to a panicogenic challenge procedure: an exper- imental evaluation of panic: vulnerability in a non-clin- ical sample. Behaviour Research and Therapy. 2006; 44(10):1421-1430. DOI:10.1016/j.brat.2005.10.012Kulkarni J. Women's mental health: an overview. Wom- en's Health Medicine. 2006;3(2):55-58. DOI:10.1383/ wohm.2006.3.2.55Kulkarni J. Women's mental health: an overview. Wom- en's Health Medicine. 2006;3(2):55-58. DOI:10.1383/ wohm.2006.3.2.55Roy-Byrne P.P., Craske M.G., Stein M.B. Panic disorder. The Lancet. 2006;3 68(9540):1023-1032. DOI:10.1016/S0140- 6736(06)69418-XRoy-Byrne P.P., Craske M.G., Stein M.B. Panic disorder. The Lancet. 2006;3 68(9540):1023-1032. DOI:10.1016/S0140- 6736(06)69418-XCombs H., Markman J. Anxiety disorders in primary care. Medical Clinics of North America. 2014;98(5):1007-1023. DOI:10.1016/j.mcna.2014.06.003Combs H., Markman J. Anxiety disorders in primary care. Medical Clinics of North America. 2014;98(5):1007-1023. DOI:10.1016/j.mcna.2014.06.003Мосолов С.Н. Клиническое применение антидепрессантов. СПб.; 1995Мосолов С.Н. Клиническое применение антидепрессантов. СПб.; 1995Цыганков Д.Б., Терехова Д.А., Агасарян Э.Г. Трудовая дезадаптация больных паническим расстройством и агора-фобией. Сибирский вестник психиатрии и наркологии. 2009;4:59-62Цыганков Д.Б., Терехова Д.А., Агасарян Э.Г. Трудовая дезадаптация больных паническим расстройством и агора-фобией. Сибирский вестник психиатрии и наркологии. 2009;4:59-62Bienvenu O.G., Onyike C.U., Stein M.B., Chen L.S., Samu- els J., Nestadt G., Eaton W.W. Agoraphobia in adults: inci- dence and longitudinal relationship with panic. The British Journal of Psychiatry. 2006;188:432-438. DOI:10.1192/ bjp.bp.105.010827Bienvenu O.G., Onyike C.U., Stein M.B., Chen L.S., Samu- els J., Nestadt G., Eaton W.W. Agoraphobia in adults: inci- dence and longitudinal relationship with panic. The British Journal of Psychiatry. 2006;188:432-438. DOI:10.1192/ bjp.bp.105.010827Международная классификация болезней (10-й пересмотр). Классификация психических и поведенческих расстройств. СПб; 1994Международная классификация болезней (10-й пересмотр). Классификация психических и поведенческих расстройств. СПб; 1994Вейн А.М., Дюкова Г.М., Воробьева О.В., Данилов А.Б. Панические атаки (руководство для врачей). М.: Эйдос Медиа; 2004Вейн А.М., Дюкова Г.М., Воробьева О.В., Данилов А.Б. Панические атаки (руководство для врачей). М.: Эйдос Медиа; 2004Баранов П.А. Паническое расстройство (клиника, диагностика, лечение): учебное пособие. Российская медицинская академия последипломного образования. М.; 2000Баранов П.А. Паническое расстройство (клиника, диагностика, лечение): учебное пособие. Российская медицинская академия последипломного образования. М.; 2000Вейн А.М., Дюкова Г.М., Воробьева О.В., Данилов А.Б. 62 Панические атаки (неврологические и психофизиологи- ческие аспекты). М.; 1997Вейн А.М., Дюкова Г.М., Воробьева О.В., Данилов А.Б. 62 Панические атаки (неврологические и психофизиологи- ческие аспекты). М.; 1997Воробьева О.В. Паническое расстройство: подходы к диагностике и терапии. Избранные лекции по неврологии. М.: Эйдос Медиа; 2006:244-264Воробьева О.В. Паническое расстройство: подходы к диагностике и терапии. Избранные лекции по неврологии. М.: Эйдос Медиа; 2006:244-264Краснов В.Н., Вельтищев Д.Ю. Невротические, тревожные и стрессовые расстройства. Психиатрия: справочник практического врача под ред. А.Г. Гофмана. М.: МЕД- пресс-информ; 2006:275-300Краснов В.Н., Вельтищев Д.Ю. Невротические, тревожные и стрессовые расстройства. Психиатрия: справочник практического врача под ред. А.Г. Гофмана. М.: МЕД- пресс-информ; 2006:275-300Dunner D.L. Management of anxiety disorders: The add- ed challenge of comorbidity. Depression and Anxiety. 2001;13(2):57-71. DOI:10.1002/da.1018Dunner D.L. Management of anxiety disorders: The add- ed challenge of comorbidity. Depression and Anxiety. 2001;13(2):57-71. DOI:10.1002/da.1018Резник А.М., Арбузов А.Л., Квашнина Н.В., Лисицына Е.А. Агорафобия и паническое расстройство с генерализацией тревоги: клиника и возможности терапии. Психиатрия и психофармакотерапия. 2004;6(6):288-291Резник А.М., Арбузов А.Л., Квашнина Н.В., Лисицына Е.А. Агорафобия и паническое расстройство с генерализацией тревоги: клиника и возможности терапии. Психиатрия и психофармакотерапия. 2004;6(6):288-291Torres A.R., Dedomenico A.M., Crepaldi A.L., Miguel E.C. Ob- sessive-compulsive symptoms in patients with panic dis- order. Comprehensive Psychiatry. 2004;45(3):219-224. DOI:10.1016/j.comppsych.2004.02.011Torres A.R., Dedomenico A.M., Crepaldi A.L., Miguel E.C. Ob- sessive-compulsive symptoms in patients with panic dis- order. Comprehensive Psychiatry. 2004;45(3):219-224. DOI:10.1016/j.comppsych.2004.02.011Johnson J.G., Cohen P., Kasen S., Brook J.S. Personality dis- orders evident by early adulthood and risk for anxiety disor- ders during middle adulthood. Journal of Anxiety Disorders. 2006;20(4):408-426. DOI:10.1016/j.janxdis.2005.06.001Johnson J.G., Cohen P., Kasen S., Brook J.S. Personality dis- orders evident by early adulthood and risk for anxiety disor- ders during middle adulthood. Journal of Anxiety Disorders. 2006;20(4):408-426. DOI:10.1016/j.janxdis.2005.06.001Татаринова Л.М. Соматоформные расстройства в отделении дневного пребывания. Психосоматические и соматоформные расстройства в современной клинической практике: материалы межрегиональной научно-практической конференции; Июнь 16-17, 2005; Иркутск, 2005. Доступно по: http://therapy.irkutsk.ru/doc/conf/conf2005ps.pdf Ссылка активна на 25.01.2017Татаринова Л.М. Соматоформные расстройства в отделении дневного пребывания. Психосоматические и соматоформные расстройства в современной клинической практике: материалы межрегиональной научно-практической конференции; Июнь 16-17, 2005; Иркутск, 2005. Доступно по: http://therapy.irkutsk.ru/doc/conf/conf2005ps.pdf Ссылка активна на 25.01.2017Joanna J., Arch J.J., Craske M.G., Stein M.B., Sherbourne C.D., Roy-Byrne P.P. Correlates of alcohol use among anxious and depressed primary care patients. General Hospital Psychiatry. 2006;28(1):37-42. DOI:10.1016/j. genhosppsych.2005.08.007Joanna J., Arch J.J., Craske M.G., Stein M.B., Sherbourne C.D., Roy-Byrne P.P. Correlates of alcohol use among anxious and depressed primary care patients. General Hospital Psychiatry. 2006;28(1):37-42. DOI:10.1016/j. genhosppsych.2005.08.007Окороков А.Н. Диагностика болезней внутренних органов: Т. 2. Диагностика ревматических и системных заболеваний соединительной ткани. Диагностика эндокринных заболеваний. М.: «Медлит»; 2008Окороков А.Н. Диагностика болезней внутренних органов: Т. 2. Диагностика ревматических и системных заболеваний соединительной ткани. Диагностика эндокринных заболеваний. М.: «Медлит»; 2008Selye H. A syndrome produced by diverse nocuous agents. Nature. 1936;138:32. DOI:doi.org/10.1038/138032a0Selye H. A syndrome produced by diverse nocuous agents. Nature. 1936;138:32. DOI:doi.org/10.1038/138032a0Mason J.W. A historical review of stress. Journal of Human Stress. 1975;1:6-12. DOI:10.1080/0097840X.1975.9940399Mason J.W. A historical review of stress. Journal of Human Stress. 1975;1:6-12. DOI:10.1080/0097840X.1975.9940399Van de Kar L.D., Blair M.L. Forebrain pathways me- diating stress-induced hormone secretion. Frontiers in Neuroendocrinology. 1999;20:1-48. DOI:10.1006/ frne.1998.0172Van de Kar L.D., Blair M.L. Forebrain pathways me- diating stress-induced hormone secretion. Frontiers in Neuroendocrinology. 1999;20:1-48. DOI:10.1006/ frne.1998.0172McEwen B.S. The neurobiology of stress: from serendipity to clinical relevance. Brain Research. 2000; 886:172-189. DOI:10.1016/S0006-8993(00)02950-4McEwen B.S. The neurobiology of stress: from serendipity to clinical relevance. Brain Research. 2000; 886:172-189. DOI:10.1016/S0006-8993(00)02950-4Wedekind D., Bandelow B., Broocks A., Hajak G., Rather E. Salivary, total plasma and plasma free cortisol in panic dis- order. Journal of Neural Transmission. 2000;107:831-837. DOI:10.1007/s007020070062Wedekind D., Bandelow B., Broocks A., Hajak G., Rather E. Salivary, total plasma and plasma free cortisol in panic dis- order. Journal of Neural Transmission. 2000;107:831-837. DOI:10.1007/s007020070062Hollander E., Liebowitz M.R., Cohen B., Gorman J.M., Fyer A., Papp L.A., Klein D.F. Cortisol and sodium lactate-in- duced panic. Psychiatry Research. 1989; 28:181-191. DOI:10.1016/0165-1781(89)90046-2Hollander E., Liebowitz M.R., Cohen B., Gorman J.M., Fyer A., Papp L.A., Klein D.F. Cortisol and sodium lactate-in- duced panic. Psychiatry Research. 1989; 28:181-191. DOI:10.1016/0165-1781(89)90046-2Bailey J.E., Argyropoulos S.V., Lightman S.L., Nutt D.J. Does the brain noradrenaline network mediate the effects of the CO2 challenge? Journal of Psychopharmacology. 2003;17:252-259. DOI:10.1177/02698811030173002Bailey J.E., Argyropoulos S.V., Lightman S.L., Nutt D.J. Does the brain noradrenaline network mediate the effects of the CO2 challenge? Journal of Psychopharmacology. 2003;17:252-259. DOI:10.1177/02698811030173002Ströhle A., Holsboer F., Rupprecht R. Increased ACTH concentrations associated with cholecystokinin tetra- peptide-induced panic attacks in patients with panic disorder. Neuropsychopharmacology. 2000;22:251-256. DOI:10.1016/S0893-133X(99)00115-3Ströhle A., Holsboer F., Rupprecht R. Increased ACTH concentrations associated with cholecystokinin tetra- peptide-induced panic attacks in patients with panic disorder. Neuropsychopharmacology. 2000;22:251-256. DOI:10.1016/S0893-133X(99)00115-3Zwanzger P., Eser D., Aicher S., Schüle C., Baghai T.C., Padberg F., Ella R., Möller H.J Rupprecht R. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study. Neuropsychopharmacology. 2003;28:979-984. DOI:10.1038/sj.npp.1300131Zwanzger P., Eser D., Aicher S., Schüle C., Baghai T.C., Padberg F., Ella R., Möller H.J Rupprecht R. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study. Neuropsychopharmacology. 2003;28:979-984. DOI:10.1038/sj.npp.1300131Хасанова Д.Р., Вагапова Г.Р., Житкова Ю.В., Абдулхаев Ф.А., Анцилевич Л.М., Сатарова Л.И. Некоторые особен- ности секреции пролактина у больных с паническими атаками различной тяжести. Неврологический вестник. 2004;36(1-2):53-58Хасанова Д.Р., Вагапова Г.Р., Житкова Ю.В., Абдулхаев Ф.А., Анцилевич Л.М., Сатарова Л.И. Некоторые особен- ности секреции пролактина у больных с паническими атаками различной тяжести. Неврологический вестник. 2004;36(1-2):53-58Bandelow B., Kaiya H. Drug treatment for panic disor- der. International Congress Series. 2006;1287:288-292. DOI:10.1016/j.ics.2005.10.008Bandelow B., Kaiya H. Drug treatment for panic disor- der. International Congress Series. 2006;1287:288-292. DOI:10.1016/j.ics.2005.10.008MacGregor E.A. Headache and hormone replacement thera- py in the postmenopausal woman. Current Treatment Options in Neurology. 2009;11:10-17. DOI:10.1007/s11940-009- 0002-zMacGregor E.A. Headache and hormone replacement thera- py in the postmenopausal woman. Current Treatment Options in Neurology. 2009;11:10-17. DOI:10.1007/s11940-009- 0002-zHalbreich U. Sex hormones and affective disorders in women. WPA Bulletin on Depression. 1999;17:6-9Halbreich U. Sex hormones and affective disorders in women. WPA Bulletin on Depression. 1999;17:6-9Dieudonnu M.N., Leneveu M.C., Giudicelli Y., Pecquery R. Evidence for functional estrogen receptors alpha and beta in human adipose cells: regional specificities and regulation by estrogens. American journal of physiology. 2004;286:655-661. DOI:10.1152/ajpcell.00321.2003Dieudonnu M.N., Leneveu M.C., Giudicelli Y., Pecquery R. Evidence for functional estrogen receptors alpha and beta in human adipose cells: regional specificities and regulation by estrogens. American journal of physiology. 2004;286:655-661. DOI:10.1152/ajpcell.00321.2003Solomon M.B., Herman J.P. Sex differences in psychopathol- ogy: of gonads, adrenals and mental Illness. Physiol Behav. 2009;97:250-258. DOI:10.1016/j.physbeh.2009.02.033Solomon M.B., Herman J.P. Sex differences in psychopathol- ogy: of gonads, adrenals and mental Illness. Physiol Behav. 2009;97:250-258. DOI:10.1016/j.physbeh.2009.02.033Martin V.T., Behbehani M. Ovarian hormones and migraine headache: understanding mechanisms and pathogene- sis: part I. Headache. The Journal of Head and Face Pain. 2006;46:3-23. DOI:10.1111/j.1526-4610.2006.00309.xMartin V.T., Behbehani M. Ovarian hormones and migraine headache: understanding mechanisms and pathogene- sis: part I. Headache. The Journal of Head and Face Pain. 2006;46:3-23. DOI:10.1111/j.1526-4610.2006.00309.xMather A.A., Cox B.J., Enns M.W., Sareen J. Associations of obesity with psychiatric disorder and suicidal be- haviours in a nationally representative sample. Journal of Psychosomatic Research. 2009;66:277-285. DOI:10.1016/j. jpsychores.2008.09.008Mather A.A., Cox B.J., Enns M.W., Sareen J. Associations of obesity with psychiatric disorder and suicidal be- haviours in a nationally representative sample. Journal of Psychosomatic Research. 2009;66:277-285. DOI:10.1016/j. jpsychores.2008.09.008Rivenes A.C., Harvey S.B., Mykletun A. The relation- ship between abdominal fat, obesity, and common men- tal disorders: results from the HUNT study. Journal of Psychosomatic Research. 2009;66:269-275. DOI:10.1016/j. jpsychores.2008.07.012Rivenes A.C., Harvey S.B., Mykletun A. The relation- ship between abdominal fat, obesity, and common men- tal disorders: results from the HUNT study. Journal of Psychosomatic Research. 2009;66:269-275. DOI:10.1016/j. jpsychores.2008.07.012Soares C.N., Poitras J.R., Prouty J. Effect of reproductive hormones and selective estrogen receptor modulators on mood during menopause. Drugs & Aging. 2003;20:85-100. DOI:10.2165/00002512-200320020-00001Soares C.N., Poitras J.R., Prouty J. Effect of reproductive hormones and selective estrogen receptor modulators on mood during menopause. Drugs & Aging. 2003;20:85-100. DOI:10.2165/00002512-200320020-00001Биологические методы терапии психических расстройств (доказательная медицина - клинической практике). Под ред. С.Н.Мосолова. М.: Социально-политическая мысль; 2012:653-657Биологические методы терапии психических расстройств (доказательная медицина - клинической практике). Под ред. С.Н.Мосолова. М.: Социально-политическая мысль; 2012:653-657Краснов В.Н. Расстройства аффективного спектра. М.: Практическая медицина; 2011:156-160Краснов В.Н. Расстройства аффективного спектра. М.: Практическая медицина; 2011:156-160Bandelow B., Broocks A., Pekrun G., George A., Meyer T., 64 Pralle L., Bartmann U., Hillmer-Vogel U., Rüther E. The use of the Panic and Agoraphobia Scale (P & A) in a controlled clinical trial. Pharmacopsychiatry. 2000;33:174-181. DOI:10.1055/s-2000-12982Bandelow B., Broocks A., Pekrun G., George A., Meyer T., 64 Pralle L., Bartmann U., Hillmer-Vogel U., Rüther E. The use of the Panic and Agoraphobia Scale (P & A) in a controlled clinical trial. Pharmacopsychiatry. 2000;33:174-181. DOI:10.1055/s-2000-12982Раевский К.С. Антидепрессанты: нейрохимические аспекты механизма действия. Психиатрия и психофармакотерапия им. П.Б. Ганнушкина. 2001;5:162-166Раевский К.С. Антидепрессанты: нейрохимические аспекты механизма действия. Психиатрия и психофармакотерапия им. П.Б. Ганнушкина. 2001;5:162-166Bandelow B., Zohar J., Hollander E., Kasper S., Möller H.-J. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post- Traumatic Stress Disorders - First Revision. The World Journal of Biological Psychiatry. 2008;9(4):248-312. DOI:10.1080/15622970802465807Bandelow B., Zohar J., Hollander E., Kasper S., Möller H.-J. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post- Traumatic Stress Disorders - First Revision. The World Journal of Biological Psychiatry. 2008;9(4):248-312. DOI:10.1080/15622970802465807Starcevic V. The reappraisal of benzodiazepines in the treat- ment of anxiety and related disorders. Expert Review of Neurotherapeutics. 2014;14(11):1275-1286. DOI:10.1586 /14737175.2014.963057Starcevic V. The reappraisal of benzodiazepines in the treat- ment of anxiety and related disorders. Expert Review of Neurotherapeutics. 2014;14(11):1275-1286. DOI:10.1586 /14737175.2014.963057Калинин В.В. Алпразолам и клоназепам при лечении панического расстройства. Новые достижения в терапии психических заболеваний под ред. С.Н. Мосолова. М.: Бином, 2002;445-449Калинин В.В. Алпразолам и клоназепам при лечении панического расстройства. Новые достижения в терапии психических заболеваний под ред. С.Н. Мосолова. М.: Бином, 2002;445-449Moroz G., Rosenbaum J.F. Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a pla- cebo-controlled, multicenter study using optimized dos- ages. The Journal of Clinical Psychiatry. 1999;60:604-612. DOI:10.4088/jcp.v60n0907Moroz G., Rosenbaum J.F. Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a pla- cebo-controlled, multicenter study using optimized dos- ages. The Journal of Clinical Psychiatry. 1999;60:604-612. DOI:10.4088/jcp.v60n0907Noyes R., Burrows G.D., Reich J.H. et al. Diazepam versus alprazolam for the treatment of panic disorder. The Journal of Clinical Psychiatry. 1996;57:349-355Noyes R., Burrows G.D., Reich J.H. et al. Diazepam versus alprazolam for the treatment of panic disorder. The Journal of Clinical Psychiatry. 1996;57:349-355Schweizer E., Pohl R., Balon R., Fox I., Rickels K., Yer- agani V.K. Lorazepam vs. alprazolam in the treatment of panic disorder. Pharmacopsychiatry. 1990; 23:90-93. DOI:10.1055/s-2007-1014489Schweizer E., Pohl R., Balon R., Fox I., Rickels K., Yer- agani V.K. Lorazepam vs. alprazolam in the treatment of panic disorder. Pharmacopsychiatry. 1990; 23:90-93. DOI:10.1055/s-2007-1014489Аведисова А.С., Ястребов Д.В. Длительное применение бензодиазепиновых транквилизаторов: распространенность и связь с формированием лекарственной зависимости. Психиатрия и психофармакотерапия им. П.Б. Ганнушкина. 2010;1:17-24Аведисова А.С., Ястребов Д.В. Длительное применение бензодиазепиновых транквилизаторов: распространенность и связь с формированием лекарственной зависимости. Психиатрия и психофармакотерапия им. П.Б. Ганнушкина. 2010;1:17-24Hoffman E.J., Mathew S.J. Anxiety disorders: a comprehen- sive review of pharmacotherapies. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medi- cine. 2008;75:248-262. DOI:10.1002/msj.20041Hoffman E.J., Mathew S.J. Anxiety disorders: a comprehen- sive review of pharmacotherapies. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medi- cine. 2008;75:248-262. DOI:10.1002/msj.20041American Psychiatric Association: Treatment of Patients with Panic Disorder ed. 2. Washington, APA; 2009American Psychiatric Association: Treatment of Patients with Panic Disorder ed. 2. Washington, APA; 2009Michelson D., Allgulander C., Dantendorfer K. et al. Effi- cacy of usual antidepressant dosing regimens of fluoxe- tine in panic disorder: randomised, placebo-controlled trial. The British Journal of Psychiatry. 2001;179:514-518. DOI:10.1192/bjp.179.6.514Michelson D., Allgulander C., Dantendorfer K. et al. Effi- cacy of usual antidepressant dosing regimens of fluoxe- tine in panic disorder: randomised, placebo-controlled trial. The British Journal of Psychiatry. 2001;179:514-518. DOI:10.1192/bjp.179.6.514Asnis G.M., Hameedi F.A., Goddard A.W., Potkin S.G., Black D., Jameel M., Desagani K., Woods S.W. Fluvoxam- ine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Research. 2001;103:1-14. DOI:10.1016/s0165- 1781(01)00265-7Asnis G.M., Hameedi F.A., Goddard A.W., Potkin S.G., Black D., Jameel M., Desagani K., Woods S.W. Fluvoxam- ine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Research. 2001;103:1-14. DOI:10.1016/s0165- 1781(01)00265-7Bandelow B. Sertraline and exposure therapy in social phobia. The British Journal of Psychiatry. 2004;184:271. DOI:10.1192/bjp.184.3.271Bandelow B. Sertraline and exposure therapy in social phobia. The British Journal of Psychiatry. 2004;184:271. DOI:10.1192/bjp.184.3.271Pollack M., Mangano R., Entsuah R., Tzanis E., Simon N.M. A randomized controlled trial of venlafaxine ER and parox- etine in the treatment of outpatients with panic disorder. Psychopharmacology. 2007;194:233-242. DOI:10.1007/ s00213-007-0821-0Pollack M., Mangano R., Entsuah R., Tzanis E., Simon N.M. A randomized controlled trial of venlafaxine ER and parox- etine in the treatment of outpatients with panic disorder. Psychopharmacology. 2007;194:233-242. DOI:10.1007/ s00213-007-0821-0Dhillon S., Scott L.G., Plosker G.L. Эсциталопрам. Обзор по применению препарата при лечении тревожных рас- стройств (часть I). Психиатрия и Психофармакотерапия. 2007;3(9):63-67Dhillon S., Scott L.G., Plosker G.L. Эсциталопрам. Обзор по применению препарата при лечении тревожных рас- стройств (часть I). Психиатрия и Психофармакотерапия. 2007;3(9):63-67Blaya C., Seganfredo A.C., Dornelles M., Torres M., Palu- do A., Heldt E., Manfro G.G. The efficacy of milnacipran in panic disorder: an open trial. International Clinical Psychopharmacology. 2007;22:153-158. DOI:10.1097/ yic.0b013e32802c7bf5Blaya C., Seganfredo A.C., Dornelles M., Torres M., Palu- do A., Heldt E., Manfro G.G. The efficacy of milnacipran in panic disorder: an open trial. International Clinical Psychopharmacology. 2007;22:153-158. DOI:10.1097/ yic.0b013e32802c7bf5Ferguson J.M., Khan A., Mangano R., Entsuah R., Tzanis E. Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended re- lease. The Journal of Clinical Psychiatry. 2007;68:58-68. DOI:10.4088/jcp.v68n0108Ferguson J.M., Khan A., Mangano R., Entsuah R., Tzanis E. Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended re- lease. The Journal of Clinical Psychiatry. 2007;68:58-68. DOI:10.4088/jcp.v68n0108Simon N.M., Kaufman R.E., Hoge E.A., Worthington J.J., Herlands N.N., Owens M.E., Pollack M.H. Open-label sup- port for duloxetine for the treatment of panic disorder. CNS Neuroscience & Therapeutics. 2009; 15:19-23. DOI:10.1111/ j.1755-5949.2008.00076.xSimon N.M., Kaufman R.E., Hoge E.A., Worthington J.J., Herlands N.N., Owens M.E., Pollack M.H. Open-label sup- port for duloxetine for the treatment of panic disorder. CNS Neuroscience & Therapeutics. 2009; 15:19-23. DOI:10.1111/ j.1755-5949.2008.00076.xБобров А.Е. Тревожные расстройства: их систематика, диагностика и фармакотерапия. Российский медицинский журнал. 2006;14(4):328-332Бобров А.Е. Тревожные расстройства: их систематика, диагностика и фармакотерапия. Российский медицинский журнал. 2006;14(4):328-332Мосолов С.Н., Смулевич А.Б., Нуллер Ю.Л., Григорьевских В.С., Костюкова Е.Г., Кузавкова М.В., Колюцкая Е.В., Андрющенко А.В., Зеленина Е.В., Косинский В.П., Козловский В.Л., Быков С.И., Перерва И.Г. Новые достижения в терапии психических заболеваний под ред. С.Н. Мосолова. М.: ЗАО «Издательство БИНОМ»; 2002:451-468Мосолов С.Н., Смулевич А.Б., Нуллер Ю.Л., Григорьевских В.С., Костюкова Е.Г., Кузавкова М.В., Колюцкая Е.В., Андрющенко А.В., Зеленина Е.В., Косинский В.П., Козловский В.Л., Быков С.И., Перерва И.Г. Новые достижения в терапии психических заболеваний под ред. С.Н. Мосолова. М.: ЗАО «Издательство БИНОМ»; 2002:451-468Emiliano A.B., Fudge J.L. From galactorrhea to osteope- nia: rethinking serotonin-prolactin interactions. Neuro- psychopharmacology. 2004;29(5):833-846. DOI:10.1038/ sj.npp.1300412Emiliano A.B., Fudge J.L. From galactorrhea to osteope- nia: rethinking serotonin-prolactin interactions. Neuro- psychopharmacology. 2004;29(5):833-846. DOI:10.1038/ sj.npp.1300412Rittenhouse P.A., Levy A.D., Li Q., Bethea C.L., Van de Kar L.D. Neurons in the hypothalamic paraventricular nucleus medi- ate the serotonergic stimulation of prolactin secretion via 5-HT1C/2 receptors. Endocrinology. 1993; 133(2):661-667. DOI:10.1210/endo.133.2.8344205#sthash.qDnnpyL5.dpufRittenhouse P.A., Levy A.D., Li Q., Bethea C.L., Van de Kar L.D. Neurons in the hypothalamic paraventricular nucleus medi- ate the serotonergic stimulation of prolactin secretion via 5-HT1C/2 receptors. Endocrinology. 1993; 133(2):661-667. DOI:10.1210/endo.133.2.8344205#sthash.qDnnpyL5.dpufJorgensen H., Knigge U., Warberg J. Involvement of 5-HT1, 5-HT2, and 5-HT3 receptors in the mediation of the prolactin response to serotonin and 5-hydroxytryptophan. Neuroendo- crinology. 1992;55(3):336-343. DOI:10.1159/000126134Jorgensen H., Knigge U., Warberg J. Involvement of 5-HT1, 5-HT2, and 5-HT3 receptors in the mediation of the prolactin response to serotonin and 5-hydroxytryptophan. Neuroendo- crinology. 1992;55(3):336-343. DOI:10.1159/000126134Fa v a G.A., Lisansky J., Buckman M.T., Kellner R., Pathak D., Fava M., Peake G.T. Prolactin, cortisol, and antidepressant treatment. American Journal of Psychiatry. 1988;145(3):358-360Fa v a G.A., Lisansky J., Buckman M.T., Kellner R., Pathak D., Fava M., Peake G.T. Prolactin, cortisol, and antidepressant treatment. American Journal of Psychiatry. 1988;145(3):358-360Meltzer H.Y., Fang V.S., Tricou B.J., Robertson A. Effect of an- tidepressants on neuroendocrine axis in humans. Advances in biochemical psychopharmacology. 1982;32:303-316Meltzer H.Y., Fang V.S., Tricou B.J., Robertson A. Effect of an- tidepressants on neuroendocrine axis in humans. Advances in biochemical psychopharmacology. 1982;32:303-316Charney D.S., Heninger G.R., Sternberg D.E. Serotonin function and mechanism of action of antidepressant treat- ment: effects of amitriptyline and desipramine. Archives of General Psychiatry. 1984;41(4):359-365. DOI:10.1001/ archpsyc.1984.01790150049008Charney D.S., Heninger G.R., Sternberg D.E. Serotonin function and mechanism of action of antidepressant treat- ment: effects of amitriptyline and desipramine. Archives of General Psychiatry. 1984;41(4):359-365. DOI:10.1001/ archpsyc.1984.01790150049008Anderson I.M., Cowen P.J. Clomipramine enhances pro- lactin and growth hormone responses to L-tryptophan. Psychopharmacology. 1986;89(1):131-133. DOI:10.1007/ BF00175205Anderson I.M., Cowen P.J. Clomipramine enhances pro- lactin and growth hormone responses to L-tryptophan. Psychopharmacology. 1986;89(1):131-133. DOI:10.1007/ BF00175205Anderson I.M., Cowen P.J. Clomipramine enhances pro- lactin and growth hormone responses to L-tryptophan. Psychopharmacology. 1986;89(1):131-133. DOI:10.1007/ BF00175205Anderson I.M., Cowen P.J. Clomipramine enhances pro- lactin and growth hormone responses to L-tryptophan. Psychopharmacology. 1986;89(1):131-133. DOI:10.1007/ BF00175205Electronic Medicines Compendium. Anafranil capsules: summary of product characteristics [online]. Available at: http://medicines.org.uk/emc. Accessed 2010, May 6Electronic Medicines Compendium. Anafranil capsules: summary of product characteristics [online]. Available at: http://medicines.org.uk/emc. Accessed 2010, May 6Egberts A.C., Meyboom R.H., De Koning F.H. et. al. Non-pu- erperal lactation associated with antidepressant drug use. British Journal of Clinical Pharmacology. 1997;44(3):277- 281. DOI:10.1046/j.1365-2125.1997.00652.xEgberts A.C., Meyboom R.H., De Koning F.H. et. al. Non-pu- erperal lactation associated with antidepressant drug use. British Journal of Clinical Pharmacology. 1997;44(3):277- 281. DOI:10.1046/j.1365-2125.1997.00652.xKapitany T., Schindl M., Shindler S.D., Heßelmann B., Füre- der T., Barnas C., Sieghart W., Kasper S.. The citalopram challenge test in patients with major depression and in healthy controls. Psychiatry Research. 1999;88(2):75-88. DOI:10.1016/S0165-1781(99)00082-7Kapitany T., Schindl M., Shindler S.D., Heßelmann B., Füre- der T., Barnas C., Sieghart W., Kasper S.. The citalopram challenge test in patients with major depression and in healthy controls. Psychiatry Research. 1999;88(2):75-88. DOI:10.1016/S0165-1781(99)00082-7Mondelli V., Gianotti L., Picu A., Daga G.A., Giordano R., Be- rardelli R., Pariante C.M., Fassino S., Ghigo E., Arvat E. Neu- roendocrine effects of citalopram infusion in anorexia ner- vosa. Psychoneuroendocrinology. 2006;31(10):1139-1148. DOI:10.1016/j.psyneuen.2006.08.006Mondelli V., Gianotti L., Picu A., Daga G.A., Giordano R., Be- rardelli R., Pariante C.M., Fassino S., Ghigo E., Arvat E. Neu- roendocrine effects of citalopram infusion in anorexia ner- vosa. Psychoneuroendocrinology. 2006;31(10):1139-1148. DOI:10.1016/j.psyneuen.2006.08.006Moeller O., Hetzel G., Rothermundt M., Michael N., Nyhuis P.W., Suslow T., Arolt V., Erfurth A. Oral citalopram and reboxe- tine challenge tests before and after selective antidepressant treatment. Journal of Psychiatric Research. 2003;37(3):261- 262. DOI:10.1016/s0022-3956(02)00102-4Moeller O., Hetzel G., Rothermundt M., Michael N., Nyhuis P.W., Suslow T., Arolt V., Erfurth A. Oral citalopram and reboxe- tine challenge tests before and after selective antidepressant treatment. Journal of Psychiatric Research. 2003;37(3):261- 262. DOI:10.1016/s0022-3956(02)00102-4Bronzo M.R., Stahl S.M. Galactorrhea induced by sertraline. American Journal of Psychiatry. 1993;150(8):1269-1270. DOI:10.1176/ajp.150.8.1269aBronzo M.R., Stahl S.M. Galactorrhea induced by sertraline. American Journal of Psychiatry. 1993;150(8):1269-1270. DOI:10.1176/ajp.150.8.1269aElectronic Medicines Compendium. Lustral: summary of product characteristics [online]. Available at: http:// medicines.org.uk/emc. Accessed 2010, May 6Electronic Medicines Compendium. Lustral: summary of product characteristics [online]. Available at: http:// medicines.org.uk/emc. Accessed 2010, May 6Electronic Medicines Compendium. Seroxat 10 mg, 20 mg, 30 mg tablets, 20mg/10mL oral suspension: summary of product characteristics [online]. Available at: http:// medicines.org.uk/emc Accessed 2010, May 6Electronic Medicines Compendium. Seroxat 10 mg, 20 mg, 30 mg tablets, 20mg/10mL oral suspension: summary of product characteristics [online]. Available at: http:// medicines.org.uk/emc Accessed 2010, May 6Daffner-Bugia C., Laakmann G., Voderholzer U., Haag C., Baghai T., Kolmsee S., Schröder U., Munz T. The neuroen- docrine effects of venlafaxine in healthy subject. Human Psychopharmacology: Clinical and Experimental. 1996;11:1- 9. DOI:10.1002/(SICI)1099-1077(199601)11:1<1::AID- HUP732>3.0.CO;2-ZDaffner-Bugia C., Laakmann G., Voderholzer U., Haag C., Baghai T., Kolmsee S., Schröder U., Munz T. The neuroen- docrine effects of venlafaxine in healthy subject. Human Psychopharmacology: Clinical and Experimental. 1996;11:1- 9. DOI:10.1002/(SICI)1099-1077(199601)11:1<1::AID- HUP732>3.0.CO;2-ZLaakmann G., Schüle C., Baghai T., Waldvogel E., Bidling- maier M., Strasburger C. Mirtazapine: an inhibitor of corti- sol secretion that does not influence growth hormone and prolactin secretion. Journal of Clinical Psychopharmacology. 2000;20:101-103. DOI:10.1097/00004714-200002000- 00019Laakmann G., Schüle C., Baghai T., Waldvogel E., Bidling- maier M., Strasburger C. Mirtazapine: an inhibitor of corti- sol secretion that does not influence growth hormone and prolactin secretion. Journal of Clinical Psychopharmacology. 2000;20:101-103. DOI:10.1097/00004714-200002000- 00019Schüle C., Baghai T., Goy J., Bidlingmaier M., Strasburger C., Laakmann G. The influence of mirtazapine on anterior pi- tuitary hormone secretion in healthy male subjects. Psy- chopharmacology. 2002;163:95-101. DOI:10.1007/s00213- 002-1148-5Schüle C., Baghai T., Goy J., Bidlingmaier M., Strasburger C., Laakmann G. The influence of mirtazapine on anterior pi- tuitary hormone secretion in healthy male subjects. Psy- chopharmacology. 2002;163:95-101. DOI:10.1007/s00213- 002-1148-5Schüle C., Baghai T., Laakmann G. Mirtazapine decreases stimulatory effects of reboxetine on cortisol, adrenocorti- cotropin and prolactin in healthy male subject. Neuroendo- crinology. 2004;79:54-62. DOI:10.1159/000076046Schüle C., Baghai T., Laakmann G. Mirtazapine decreases stimulatory effects of reboxetine on cortisol, adrenocorti- cotropin and prolactin in healthy male subject. Neuroendo- crinology. 2004;79:54-62. DOI:10.1159/000076046Baumgartner A., Campos-Barros A., Meinhold M.S.H. Chron- ic desipramine treatment enhances thyroxine deiodina- tion in rat brain. Psychiatry Research. 1990;34:217-219. DOI:10.1016/0165-1781(90)90022-wBaumgartner A., Campos-Barros A., Meinhold M.S.H. Chron- ic desipramine treatment enhances thyroxine deiodina- tion in rat brain. Psychiatry Research. 1990;34:217-219. DOI:10.1016/0165-1781(90)90022-wJoffe R.T., Singer W. The effects of tricyclic antide- pressants on basal thyroid hormone levels in de- pressed patients. Pharmacopsychiatry. 1990;23:67-69. DOI:10.1055/s-2007-1014485Joffe R.T., Singer W. The effects of tricyclic antide- pressants on basal thyroid hormone levels in de- pressed patients. Pharmacopsychiatry. 1990;23:67-69. DOI:10.1055/s-2007-1014485Rousseau A., Comby F., Buxeraud J., Raby C. Spectroscopic analysis of charge transfer complex formation and peroxi- dase inhibition with tricyclic antidepressant drugs: Poten- tial anti-thyroid action. Biological & Pharmaceutical Bulle- tin. 1996;19(5):726-728. DOI:10.1248/bpb.19.726Rousseau A., Comby F., Buxeraud J., Raby C. Spectroscopic analysis of charge transfer complex formation and peroxi- dase inhibition with tricyclic antidepressant drugs: Poten- tial anti-thyroid action. Biological & Pharmaceutical Bulle- tin. 1996;19(5):726-728. DOI:10.1248/bpb.19.726Shelton R. C., Winn S., Ekhatore N., Loosen P. T. The effects of antidepressants on the thyroid axis in depression. Bio- logical Psychiatry. 1993;33:120-126. DOI:10.1016/0006- 3223(93)90311-zShelton R. C., Winn S., Ekhatore N., Loosen P. T. The effects of antidepressants on the thyroid axis in depression. Bio- logical Psychiatry. 1993;33:120-126. DOI:10.1016/0006- 3223(93)90311-zScanlon M.F., Peters J., Foord S., Dieguez C., Hall R. The clinical relevance of TRH in diagnosis and investigation. In: Griffiths E.L., Bonnet G.W., eds. Thyrotropin-Releasing- Hormone. New York: Raven Press; 1983:303-314Scanlon M.F., Peters J., Foord S., Dieguez C., Hall R. The clinical relevance of TRH in diagnosis and investigation. In: Griffiths E.L., Bonnet G.W., eds. Thyrotropin-Releasing- Hormone. New York: Raven Press; 1983:303-314Brady K.T., Anton R.F. The thyroid axis and desipramine treatment in depression. Biological Psychiatry. 1989;25:703- 709. DOI:10.1016/0006-3223(89)90241-2Brady K.T., Anton R.F. The thyroid axis and desipramine treatment in depression. Biological Psychiatry. 1989;25:703- 709. DOI:10.1016/0006-3223(89)90241-2Morley J.E., Brammer G.L., Sharp B., Yamada T., Yuwiler A., Hershman J.M. Neurotransmitter control of hypothalamic- pituitary-thyroid function in rats. European Journal of Pharmacology. 1981;70:263-271. DOI:10.1016/0014- 2999(81)90159-xMorley J.E., Brammer G.L., Sharp B., Yamada T., Yuwiler A., Hershman J.M. Neurotransmitter control of hypothalamic- pituitary-thyroid function in rats. European Journal of Pharmacology. 1981;70:263-271. DOI:10.1016/0014- 2999(81)90159-xFatimi J., Lagorce J.F., Chabernaud M.L., Comby F., Buxeraud J., Raby C. Synthesis and antithyroid activity of 1,4,5-trialkyl 2-thioimidazole derivatives. Fharmacology. 1994;49(4):253-257Fatimi J., Lagorce J.F., Chabernaud M.L., Comby F., Buxeraud J., Raby C. Synthesis and antithyroid activity of 1,4,5-trialkyl 2-thioimidazole derivatives. Fharmacology. 1994;49(4):253-257Joffe R.T., Sokolov S.T. Thyroid hormones, the brain, and affective disorders. Journal Critical Reviews in Neurobiology. 1994;8(2):45-63Joffe R.T., Sokolov S.T. Thyroid hormones, the brain, and affective disorders. Journal Critical Reviews in Neurobiology. 1994;8(2):45-63Gitlin M., Altshuler L.L., Frye M.A. Peripheral thyroid hormones and response to selective serotonin reuptake inhibitors. Journal Psychiatry Neuroscience. 2004;29(5):383-386Gitlin M., Altshuler L.L., Frye M.A. Peripheral thyroid hormones and response to selective serotonin reuptake inhibitors. Journal Psychiatry Neuroscience. 2004;29(5):383-386De Carvalho G.A., Bahls S.C., Boeving A., Graf H. Effects of selective serotonin reuptake inhibitors on thyroid function in depressed patients with primary hypothyroidism or normal thyroid function. Thyroid. 2009;19(7):691-697. DOI:10.1089/thy.2008.0261De Carvalho G.A., Bahls S.C., Boeving A., Graf H. Effects of selective serotonin reuptake inhibitors on thyroid function in depressed patients with primary hypothyroidism or normal thyroid function. Thyroid. 2009;19(7):691-697. DOI:10.1089/thy.2008.0261Gambi F., De Berardis D., Sepede G., Campanella D., Galliani N., Carano A., La Rovere R., Salini G., Penna L., Cicconetti A., Spinella S., Quartesan R., Salerno R.M., Ferro F.M. Effect of mirtazapine on thyroid hormones in adult patients with major depression. International Journal of Immunopathology and Pharmacology. 2005;18(4):737- 744. DOI:10.1177/039463200501800417Gambi F., De Berardis D., Sepede G., Campanella D., Galliani N., Carano A., La Rovere R., Salini G., Penna L., Cicconetti A., Spinella S., Quartesan R., Salerno R.M., Ferro F.M. Effect of mirtazapine on thyroid hormones in adult patients with major depression. International Journal of Immunopathology and Pharmacology. 2005;18(4):737- 744. DOI:10.1177/039463200501800417Eker S.S., Akkaya C., Cangur S., Sarandol A., Kirli S. Effects of various antidepressants on serum thyroid hormone levels in patients with major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2008;32(4):955-961. DOI:10.1016/j.pnpbp.2007.12.029Eker S.S., Akkaya C., Cangur S., Sarandol A., Kirli S. Effects of various antidepressants on serum thyroid hormone levels in patients with major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2008;32(4):955-961. DOI:10.1016/j.pnpbp.2007.12.029Serretti A., Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. Journal Clinical Psychiatry. 2010;71:1259-1272. DOI:10.4088/ JCP.09r05346bluSerretti A., Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. Journal Clinical Psychiatry. 2010;71:1259-1272. DOI:10.4088/ JCP.09r05346bluKhoza S., Barner J.C. Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports. International Journal of Clinical Pharmacy. 2011;33:484-492. DOI:10.1007/s11096-011-9507-0Khoza S., Barner J.C. Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports. International Journal of Clinical Pharmacy. 2011;33:484-492. DOI:10.1007/s11096-011-9507-0Sansone R.A., Sansone L.A. Driving on antidepressants: cruising for a crash? Psychiatry (Edgmont). 2009;6:13-16Sansone R.A., Sansone L.A. Driving on antidepressants: cruising for a crash? Psychiatry (Edgmont). 2009;6:13-16Mezuk B., Johnson-Lawrence V., Lee H., Rafferty J.A., Ab- 68 dou C.M., Uzogara E.E., Jackson J.S. Is ignorance bliss? De- pression, antidepressants, and the diagnosis of prediabetes and type 2 diabetes. Health Psychology. 2013;32:254-263. DOI:10.1037/a0029014Mezuk B., Johnson-Lawrence V., Lee H., Rafferty J.A., Ab- 68 dou C.M., Uzogara E.E., Jackson J.S. Is ignorance bliss? De- pression, antidepressants, and the diagnosis of prediabetes and type 2 diabetes. Health Psychology. 2013;32:254-263. DOI:10.1037/a0029014Pyykkönen A.-J., Räikkönen K., Tuomi T., Eriksson J.G., Groop L., Isomaa B. Association between depressive symptoms and metabolic syndrome is not explained by antidepressant medication: results from the PPP-Botnia Study. Annals of Medicine. 2012;44:279-288. DOI:10.3109/07853890.201 0.543921Pyykkönen A.-J., Räikkönen K., Tuomi T., Eriksson J.G., Groop L., Isomaa B. Association between depressive symptoms and metabolic syndrome is not explained by antidepressant medication: results from the PPP-Botnia Study. Annals of Medicine. 2012;44:279-288. DOI:10.3109/07853890.201 0.543921Brown L.C., Majumdar S.R., Johnson J.A. Type of antide- pressant therapy and risk of type 2 diabetes in people with depression. Diabetes Research and Clinical Practice. 2008;79:61-67. DOI: 10.1016/j.diabres.2007.07.009Brown L.C., Majumdar S.R., Johnson J.A. Type of antide- pressant therapy and risk of type 2 diabetes in people with depression. Diabetes Research and Clinical Practice. 2008;79:61-67. DOI: 10.1016/j.diabres.2007.07.009Khoza S., Barner J.C., Bohman T.M., Rascati K., Lawson K., Wilson J.P. Use of antidepressant agents and the risk of type 2 diabetes. European Journal of Clinical Pharmacology. 2012;68:1295-1302. DOI:10.1007/s00228-011-1168-3Khoza S., Barner J.C., Bohman T.M., Rascati K., Lawson K., Wilson J.P. Use of antidepressant agents and the risk of type 2 diabetes. European Journal of Clinical Pharmacology. 2012;68:1295-1302. DOI:10.1007/s00228-011-1168-3Kivimäki M., Hamer M., Batty G.D., Geddes J.R., Tabak A.G., Pentti J., Virtanen M., Vahtera J. Antidepressant medication use, weight gain, and risk of type 2 diabetes: a populationbased study. Diabetes Care. 2010;33:2611-2616. DOI:10.2337/dc10-1187Kivimäki M., Hamer M., Batty G.D., Geddes J.R., Tabak A.G., Pentti J., Virtanen M., Vahtera J. Antidepressant medication use, weight gain, and risk of type 2 diabetes: a populationbased study. Diabetes Care. 2010;33:2611-2616. DOI:10.2337/dc10-1187Hennings J.M., Schaaf L., Fulda S. Glucose metabolism and antidepressant medication. Current Pharmaceutical Design. 2012;18:5900-5919. DOI:10.2174/138161212803523662Hennings J.M., Schaaf L., Fulda S. Glucose metabolism and antidepressant medication. Current Pharmaceutical Design. 2012;18:5900-5919. DOI:10.2174/138161212803523662Prezegaliński E., Budziszewska B. The effect of long-term treatment with antidepressant drugs on the hippocampal mineralocorticoid and glucocorticoid receptors in rats. Neu- roscience Letters. 1993;161:215-218. DOI:10.1016/0304- 3940(93)90297-xPrezegaliński E., Budziszewska B. The effect of long-term treatment with antidepressant drugs on the hippocampal mineralocorticoid and glucocorticoid receptors in rats. Neu- roscience Letters. 1993;161:215-218. DOI:10.1016/0304- 3940(93)90297-xSeckl J.R., Fink G. Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hip- pocampus in vivo. Neuroendocrinology. 1992;55:621-626. DOI:10.1159/000126180Seckl J.R., Fink G. Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hip- pocampus in vivo. Neuroendocrinology. 1992;55:621-626. DOI:10.1159/000126180Mitchell J.B., Rowe W., Boksa P., Meaney M.J. Serotonin regulates type II corticosteroid receptor binding in hippocampal cell cultures. Journal of Neuroscience. 1990;10:1745-1752Mitchell J.B., Rowe W., Boksa P., Meaney M.J. Serotonin regulates type II corticosteroid receptor binding in hippocampal cell cultures. Journal of Neuroscience. 1990;10:1745-1752Holsboer F. The corticosteroid receptor hypothesis of de- pression. Neuropsychopharmacology. 2000;23:477-501. DOI:10.1016/s0893-133x(00)00159-7Holsboer F. The corticosteroid receptor hypothesis of de- pression. Neuropsychopharmacology. 2000;23:477-501. DOI:10.1016/s0893-133x(00)00159-7Pariante C.M., Miller A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biological Psychiatry. 2001;49:391-404. DOI:10.1016/ s0006-3223(00)01088-xPariante C.M., Miller A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biological Psychiatry. 2001;49:391-404. DOI:10.1016/ s0006-3223(00)01088-xRatka A., Sutanto W., Bloemers M., De Kloet E.R. On the role of brain mineralocorticoid (type I) and glucocorticoid (type II) receptors in neuroendocrine regulation. Neuroendocri- nology. 1989;50:117-123. DOI:10.1159/000125210Ratka A., Sutanto W., Bloemers M., De Kloet E.R. On the role of brain mineralocorticoid (type I) and glucocorticoid (type II) receptors in neuroendocrine regulation. Neuroendocri- nology. 1989;50:117-123. DOI:10.1159/000125210Fadda P., Pani L., Porcella A., Fratta W. Chronic imipramine, L-sulpiride and mianserin decrease corticotropin releas- ing factor levels in the rat brain. Neuroscience Letters. 1995;192:121-123. DOI:10.1016/0304-3940(95)11612-zFadda P., Pani L., Porcella A., Fratta W. Chronic imipramine, L-sulpiride and mianserin decrease corticotropin releas- ing factor levels in the rat brain. Neuroscience Letters. 1995;192:121-123. DOI:10.1016/0304-3940(95)11612-zHolsboer F., Barden N. Antidepressants and hypothalam- ic-pituitary-adrenocortical regulation. Endocrine Reviews. 1996;17:187-205. DOI:10.1210/edrv-17-2-187Holsboer F., Barden N. Antidepressants and hypothalam- ic-pituitary-adrenocortical regulation. Endocrine Reviews. 1996;17:187-205. DOI:10.1210/edrv-17-2-187De Bellis M.D., Gold P.W., Geracioti T.D.Jr., Listwak S.J., Kling M.A. Association of fluoxetine treatment with re- ductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. American Journal of Psychiatry. 1993;150:656- 657. DOI:10.1176/ajp.150.4.656De Bellis M.D., Gold P.W., Geracioti T.D.Jr., Listwak S.J., Kling M.A. Association of fluoxetine treatment with re- ductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. American Journal of Psychiatry. 1993;150:656- 657. DOI:10.1176/ajp.150.4.656

The authors declare that there are no conflicts of interest present.